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ways promoting intrahepatic fatty acid accumulation in methionine and
choline deficiency: implications for the pathogenesis of steatohepatitis.
Am J Physiol Endocrinol Metab 300: E402–E409, 2011. First published
November 30, 2010; doi:10.1152/ajpendo.00331.2010.—The patholog-
ical mechanisms that distinguish simple steatosis from steatohepatitis
(or NASH, with consequent risk of cirrhosis and hepatocellular
cancer) remain incompletely defined. Whereas both a methionine- and
choline-deficient diet (MCDD) and a choline-deficient diet (CDD)
lead to hepatic triglyceride accumulation, MCDD alone is associated
with hepatic insulin resistance and inflammation (steatohepatitis). We
used metabolic tracer techniques, including stable isotope ([13C4]palmitate)
dilution and mass isotopomer distribution analysis (MIDA) of [13C2]acetate,
to define differences in intrahepatic fatty acid metabolism that could explain
the contrasting effect of MCDD and CDD on NASH in C57Bl6 mice.
Compared with control-supplemented (CS) diet, liver triglyceride pool sizes
were similarly elevated in CDD and MCDD groups (24.37 2.4, 45.94
3.9, and 43.30 3.5mol/liver for CS, CDD, and MCDD, respectively), but
intrahepatic neutrophil infiltration and plasma alanine aminotransferase
(31  3, 48  4, 231  79 U/l, P  0.05) were elevated only in MCDD
mice. However, despite loss of peripheral fat in MCDD mice, neither the rate
of appearance of palmitate (27.2  3.5, 26.3  2.3, and 28.3  3.5
mol·kg1·min1) nor the contribution of circulating fatty acids to the liver
triglyceride pool differed between groups. Unlike CDD, MCDD had a defect
in hepatic triglyceride export that was confirmed using intravenous tyloxapol
(142 21, 122 15, and 80  7 mg·kg1·h1, P  0.05). Moreover,
hepatic de novo lipogenesis was significantly elevated in the MCDD
group only (1.4 0.3, 2.3  0.4, and 3.4  0.4 mol/day, P  0.01).
These findings suggest that important alterations in hepatic fatty
acid metabolism may promote the development of steatohepatitis.
Similar mechanisms may predispose to hepatocyte damage in
human NASH.
nonalcoholic fatty liver disease; steatohepatitis; free fatty acids; de
novo lipogenesis; methionine- and choline-deficient diet; choline-
deficient diet
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) is an increasingly
recognized entity encompassing a spectrum of severity ranging
from uncomplicated triglyceride accumulation (or steatosis) to
inflammation (steatohepatitis), fibrosis, cirrhosis, and hepatocel-
lular carcinoma (31). The mechanisms underlying susceptibility to
progressive liver disease in NAFLD remain poorly understood.
Importantly, it is not known whether specific changes in hepatic
triglyceride handling leading to the accumulation of intracellular
fatty acids predispose to hepatocyte damage and the development
of nonalcoholic steatohepatitis (NASH).
Broadly speaking, the accumulation of hepatic triglyceride
can be considered an imbalance between the supply of free
fatty acids (FFAs) from both plasma and intrahepatic de novo
lipogenesis (DNL) and their removal by either fatty acid
oxidation or export in very low-density lipoprotein (VLDL).
Studies in humans suggest that both increased release of FFAs
from extrahepatic tissues and increased DNL contribute to the
accumulation of liver triglyceride in NAFLD (8–10). Such
abnormalities of fatty acid metabolism may play a role not only
in the insulin resistance associated with NAFLD but also in
promoting hepatic inflammation. In addition to influencing
rates of hepatic gluconeogenesis and VLDL export (6, 25),
FFAs are inherently toxic to hepatocytes (30), e.g., activating
the proinflammatory cytokine nuclear transcription factor-B
(12, 19) and upregulating mediators of apoptosis (11). A toxic
role for FFAs in the liver is supported by the observation that
inhibiting diacylglycerol acyltransferase 2, the final enzyme in
the pathway esterifying fatty acids to triglycerides, promotes
steatohepatitis and liver fibrosis in mice despite reducing in-
trahepatic triglycerides (45).
In humans, practical limitations mean that only the broadest
association can be made between hepatic triglyceride/fatty acid
handling and NASH. In contrast, the mechanisms underlying
susceptibility to steatohepatitis and fibrosis mediated by fatty
acids can be defined by studies in animal models with con-
trasting susceptibility to NASH. Feeding rodents diets deficient
in choline and/or methionine reliably leads to the accumulation
of intrahepatic triglyceride (15, 32), but there are contrasting
consequences for liver inflammation. A methionine- and cho-
line-deficient diet (MCDD) causes steatohepatitis and hepatic
insulin resistance (24, 37, 39), although peripheral insulin
sensitivity is improved due to significant weight loss (38). In
contrast, a simple choline-deficient diet (CDD) leads to steato-
sis without significant inflammation and is associated with
improved hepatic and peripheral insulin sensitivity without
weight loss following a high-fat diet (36). These diets provide
readily tractable models to define the differences in hepatic
fatty acid metabolism that underlie susceptibility to NASH as
opposed to simple steatosis.
Impaired VLDL export was previously thought to be the
dominant mechanism for the accumulation of liver fat in both
CDD and MCDD models (29). More recent ex vivo studies
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have shown that VLDL export may not be decreased in CDD
mice (22), whereas alterations in gene expression support the
hypothesis that a primary increase in fatty acid esterification
protects CDD mice against the toxic effects of intrahepatic
fatty acids (36). Moreover, weight loss in MCDD but not CDD
mice suggests that increased flux of potentially toxic FFAs
from the periphery to the liver may occur only with MCDD.
However, these inferences concerning fatty acid metabolism in
MCDD and CDD mice are drawn indirectly from ex vivo
measurements. We have characterized fatty acid metabolism in
detail in vivo using stable isotope tracers in mice fed CDD and
MCDD and identified pathways that could explain contrasting
propensity to hepatocyte damage and steatohepatitis in these
models, observations with implications for understanding the
pathogenesis of human NASH.
MATERIALS AND METHODS
Materials
Stable isotope-labeled tracers were from Cambridge Isotopes (An-
dover, MA), and all other chemicals were from Sigma (Poole, UK)
unless otherwise stated. Solvents were glass-distilled HPLC grade
(Rathburn, Walkerburn, UK). Human albumin solution (20%) was
from the Scottish National Blood Transfusion Service (Lothian, UK).
Animals and Procedures
All experiments were carried out under a UK Home Office animal
license. Twelve-week-old male C57BL/6J mice (Harlan, Bicester,
UK) were maintained under controlled conditions of light and tem-
perature. Following a 2-wk period of acclimatization, mice were
offered either control (choline and methionine supplemented; CS)
chow, CDD, or MCDD (Dyets, Bethlehem, PA) for 2 wk. The dietary
compositions are shown in Table 1; to prevent unavoidable contam-
ination of choline and methionine from protein, the protein content
was replaced by pure L-amino acids (32).
Fatty Acid Flux Studies
To quantify FFA turnover by stable isotope dilution, 1,2,3,4-
[13C4]palmitate was infused intravenously (n  12–15 mice/group),
and tracer enrichment of the palmitate pool in liver, adipose tissue,
and plasma was measured by gas chromatography-mass spectrometry
(GC-MS) (1).
Jugular venous cannulae were inserted under general anesthesia (in-
traperitoneal medetomidine and ketamine) on day 10 of dietary manip-
ulations, and mice were allowed 4 days to recover prior to tracer
infusions. [13C4]palmitate was prepared by dissolving its potassium salt
in saline and complexing with 20% wt/vol albumin solution at 40°C. In
initial studies, a stock solution was diluted so that infusion at 5 l/min
provided 0.271 mol·kg1·min1 tracer (1, 20). Following preliminary
analysis, the concentration was later increased so that the infusion
delivered 0.542 mol·kg1·min1 to increase tissue enrichment. Calcu-
lated kinetic results were similar in both groups, so data were combined
for statistical analysis. Following a 4-h fast, the tracer infusion was
commenced using a Harvard apparatus syringe pump (World Precision
Instruments, Stevenage, UK) for 180 min (20). Animals were euthanized
by decapitation within 60 s of being disturbed, and trunk blood was
collected on wet ice. Plasma was stored at 80°C. Liver and adipose
depots were immediately harvested, weighed, and snap-frozen on dry ice.
Palmitate and its tracer were quantified by GC-MS and triglycerides (TG)
by spectrophotometric assay as detailed below.
Kinetic Calculations
Assuming steady-state conditions after 180 min of infusion (1), the
rate of appearance (Ra) of palmitate in plasma was calculated using
Eq. 1:
Ramol · kg1 · min1 F/IE, (1)
where F is the isotope infusion rate (mol·kg1·min1) and IE is the
isotopic enrichment (the tracer/tracee ratio).
An index of the contribution of circulating FFAs to TG pools in
tissues and plasma was estimated using Eq. 2 (1, 8, 20):
Fraction of TG palmitate derived from plasma FFA
IE of [13C4] palmitate in TG
palmitate ⁄ IE of [13C4] palmitate in plasma.
(2)
The absolute contribution of circulating palmitate to tissue or plasma
TGs was calculated by correcting for the TG pool size using Eq. 3:
Absolute palmitate uptake
fraction of TG palmitate derived from plasma  TG pool size, (3)
where tissue and plasma TG pool sizes were calculated by multiplying
TG concentration by tissue weight [assuming adipose tissue to be
composed of pure TG of molecular weight 861 (14)] or estimated
plasma volume [3.5% of body weight (18)], respectively.
DNL Studies
To assess DNL, in other groups of mice (n  8/group), [13C2]acetate
was added to diets for 5 days before euthanization and incorporation of
13C into TG assessed in liver and plasma using mass isotopomer distri-
bution analysis (MIDA) after analysis of TG-derived palmitate and its
labeled isotopomers by GC-MS (1, 17). Mice were housed individually
and fed diets as described above in a paste (225 g of powdered chow as
described above with 45 ml of water) packed into 50-ml plastic tubes to
facilitate weighing of food intake. For the final 5 days, labeled
[13C2]acetate (4.5 g) was added to the water before preparation of the
paste. Tissues were collected as described above. Snap-frozen livers from
these mice were also used for real-time PCR studies.
MIDA
GC-MS was used to determine the pattern of incorporation of
[13C2]acetate into newly synthesized hepatic TG FFAs using the
method of Chinkes et al. (7), and the fractional synthesis rate, i.e., the
fraction of the liver TG-palmitate pool synthesized per unit of time,
was calculated using Eq. 4:
FSR Ebt2 Ebt1 ⁄ t2 t1 EF , (4)
where FSR is the fractional synthesis rate, Eb is the singly labeled
product (palmitate) enrichment at time points t2 and t1 in moles
percent excess (MPE), and EF is the calculated precursor (acetyl-
Table 1. Composition of rodent diets
CS CDD MCDD
Kcal/g 4.3 4.3 4.3
Kcal%
Protein (as L-amino acids) 15 15 15
Carbohydrate 55 55 55
Fat 30 30 30
Choline bitartate, g/kg 14.48 0 0
L-Methionine, g/kg 1.7 1.7 0
CS, control diet; CDD, choline-deficient diet; MCDD, methionine- and
choline-deficient diet. Diets were purchased from Dyets (Bethlehem, PA), with
the following manufacturers’ reference codes: CS, 518574; CDD, 518753;
MCDD, 518810. All diets contained 50 g/kg corn oil (source of polyunsatu-
rated fat) and 100 g/kg Primex (hydrogenated vegetable oil) as lipid sources.
Carbohydrate was composed of corn starch, dextrin, cellulose, and sucrose,
with sucrose differing marginally between the groups (392, 406, and 408 g/kg
for the CS, CDD, and MCDD, respectively).
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CoA) enrichment converted into the same units of singly labeled
product enrichment using Eq. 5 (7). Baseline enrichment (t1) was
determined from the livers from the VLDL export experiment.
EF n p l pn  l , (5)
where p is the calculated precursor enrichment in MPE and n is the
maximum number of acetyl-CoA molecules that could appear in
palmitate (i.e., 8), as described in detail elsewhere (7).
The absolute synthesis rate was calculated by multiplying the FSR
by the size of the TG pool (in mol), estimated as described above.
The same calculations were used to calculate the export of newly
synthesised fatty acids into the plasma TG pool.
Hepatic TG Export Studies
In additional mice (n  7–8/group), following a 4-h fast, hepatic
VLDL export was assessed by measuring the rate of accumulation of
TG (quantified by spectrophotometry) in plasma from serial tail nicks
taken at 0, 30, 60, 120, and 180 min following administration of
tyloxapol (Triton W1339) by tail vein injection (500 mg/kg, 15%
vol/vol in normal saline) (26). Eq. 6 converted the Ra per plasma
volume into whole body Ra, and plasma volume was estimated as
3.5% of body weight (18).
TG export mg · kg1 · h1
slope of linemg · dl1 · min1
 estimated plasma volume dl ⁄ weightkg 60 .
(6)
Hepatic Inflammation Studies
In an additional study (n  10/group), livers were fixed in 10%
formalin for immunohistochemical analysis after 2 wk of dietary
interventions, as described above. In addition, fasting plasma samples
from these mice were used for measurement of liver function tests and
total plasma FFAs.
Biochemical Assays
Lipid extraction. Palmitate and its tracer were extracted from plasma
(50 l) containing heptadecanoic acid (5 g) internal standard and
derivatized to their methyl esters (33) prior to analysis by GC-MS. For
analysis of TGs, plasma and tissue lipids were extracted using a modified
Folch technique (13) with triheptadecanoic acid (5 g) internal standard,
and TGs were separated by solid-phase extraction using aminopropyl
silica cartridges (100 mg; Bondelut Varian, Harbor City, CA), ensuring
that the columns remained wetted between samples. TGs were hydro-
lyzed to their constituent FFAs and derivatized to their methyl esters
using acidified methanol (2% vol/vol) sulphuric acid (34%) in methanol
(18 h, 50°C) prior to extraction into hexane (4).
GC-MS analysis of palmitate. GC-MS analysis was undertaken on
a ThermoFinnigan Voyager gas chromatograph mass spectrometer
with an Agilent HP-Innowax column (30 m, 0.320 mm, 0.5 m)
operated in electron impact ionization mode (70 eV). Source, inter-
face, and injection temperatures were 200, 250, and 260°C, respec-
tively. The column temperature was programmed from a 1.5-min hold
at 50°C, with a 13°C/min ramp and a 1.5-min hold at 260°C. Fatty
acid methyl esters derived from plasma FFA and TG pools were
analyzed using selective ion monitoring of molecular ions with
mass-to-charge ratios of 270, 272, 274, and 284, corresponding to
[M  0], [M  2], and [M  4] isotopomers of methyl palmitate and
the methyl heptadecanoate internal standard, respectively. To avoid
concentration-dependent effects of methyl palmitate on ionization,
each sample was analyzed several times using a range of injection
volumes, as described previously (34).
Enzymatic assays. Plasma and liver TGs were quantified enzymat-
ically using a colorimetric assay (Infinity; ThermoTrace), as described
previously (36). Plasma FFAs were measured in duplicate using a
commercial kit (Wako, Fuggerstrabe, Germany), and liver function
tests, including alanine aminotransferase and aspartate aminotransfer-
ase, were measured using commercial colorimetric kits (Randox
Laboratories, Antrim, UK) adapted for use on a Cobras centrifugal
analyzer (Roche Dignostics, Welwyn Garden City, UK).
Quantitative Real-Time PCR
Total hepatic mRNA was extracted using a Qiagen RNeasy extrac-
tion kit (Crawley, UK) per the manufacturer’s instructions and quan-
tified at 260/280. Integrity was checked by agarose gel electrophore-
sis (n  6–8/group). Complementary DNA was synthesized from 0.5
g of mRNA following genomic DNA wipeout using the Qiagen
reverse transcription kit. Quantification of hepatic gene transcription
was performed by real-time PCR using the Roche (Burgess Hill, UK)
lightcycler 480 system. Primers and probes were from the Roche UPL
library. The relative amount of mRNA was derived from standard
curves prepared from serial dilutions of complementary DNA, and
transcript levels were normalized to mean values of TBP and 	-actin
as housekeeping genes.
Immunohistochemistry
Paraffin-embedded sections of liver were stained using an anti-
granulocyte antibody (108413 rat anti-mouse GR1 antibody; Cam-
bridge Biosciences, Cambridge, UK). Liver sections were dewaxed in
xylene and rehydrated in alcohol, and endogenous peroxide activity
was blocked by washing in 1% hydrogen peroxide solution. After
washing in phosphate-buffered saline (PBS), slides were mounted in
Shandon Sequenza racks (Thermo Fisher Scientific, Leics, UK). A
Fig. 1. Effect of methionine  choline deficiency on
body weight. Data points represent means SE; n
8–30/group depending on time point. Final weights
were analyzed by 1-way ANOVA with Tukey’s post
hoc comparison test. CS, control diet; CDD, choline-
deficient diet; MCDD, methionine- and choline-de-
ficient diet. *P  0.05; ***P  0.001.
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commercial avidin-biotin blocking kit (Vector Laboratories, Burlin-
game, CA) was used to block any background staining, and washing
with PBS (
3) occurred between stages. Sections were blocked using
normal rabbit serum (DAKO, Ely, UK) diluted 1:4 in PBS, with
incubation occurring for 30 min at room temperature. Samples were
then incubated with a 1-in-200 dilution (in rabbit serum) of the
primary anti-granulocyte antibody (108413 rat anti-mouse GR1 anti-
body; Cambridge Biosciences) overnight at 4°C. After 0.1% Tween
and PBS washes, sections were incubated for 60 min at room tem-
perature, with a 1:300 dilution (in normal rabbit serum) of the
secondary rabbit anti-rat antibody (DAKO) for 30 min at room
temperature. Sections were incubated with three drops of the Vector
RTU ABC reagent (30 min at room temperature) and anti-GR1
positive cells visualized using diaminobenzidine staining. Sections
were counterstained in hemotoxylin (15 s) and blued in Scott’s tap
water (5 s) prior to dehydration through alcohol, clearing in xylene,
and mounting in DPX mountant. Cell counts of neutrophils were
undertaken in a blinded manner, averaging the number of cells in 40
representative high-power fields (
400) per liver section.
Statistical Analysis
Results are presented as means  SE and were compared by
one-way ANOVA with Tukey’s post hoc multiple comparison test
when appropriate.
Table 2. Effect of choline  methionine deficiency on liver weights and TGs, adipose depot weights, and food intake
CS CDD MCDD
Liver weight, %body weight 4.0  0.1 4.7  0.1*** 3.8  0.1†††
Liver TG pool, mol/liver$ 24.37  2.4 45.94  3.9*** 43.30  3.5***
Adipose depot weights, %body wt
Subcutaneous$ 1.5  0.2 1.3  0.1 0.7  0.1***††
Epididymal$ 1.6  0.1 1.4  0.1 0.4  0.0***†††
Mesenteric§ 0.3  0.1 0.4  0.1 0.1  0.0*†††
Food intake, g  kg body wt1  day1§ 127.9  4.5 130.8  2.8 104  2.7***†††
Liver function tests§
Bilirubin, mol/l 4.9  0.8 4.5  0.7 5.3  0.6
ALT, U/l 31  3 48  4 231  79†*
AST, U/l 303  86 224  22 507  90†
Data are means  SE, analyzed by 1-way ANOVA with Tukey’s post hoc tests where appropriate. TG, triglyceride; ALT, alanine aminotransferase; AST,
aspartate aminotransferase. *P  0.05, ***P  0.001 vs. CS; †P  0.05, ††P  0.01, and †††P  0.001 vs. CDD. Data were collected in different experiments
and combined here, hence the varying numbers; $n  21–23/group, §n  7–8/group. For all other variables, n  28–30/group.
Fig. 2. Effects of methionine  choline defi-
ciency on liver inflammatory cell infiltration.
Data are means  SE for n  10/group. Two
weeks of MCDD but not CDD produced an
increase in neutrophil staining. A: average
cell counts of anti-GR1-positive staining cells
per high-power fields; **P  0.05. Exem-
plary GR1-positive staining cells in CS group
(B), CDD (C), and MCDD (D). Original mag-
nification, 
250. Arrows indicate immu-
nopositive cells.
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RESULTS
Body Composition and Liver TGs
Consistent with previous studies (37, 39), mice on MCDD
lost weight (Fig. 1), with marked loss of both subcutaneous and
epididymal fat (Table 2). CDD mice gained weight but less
than mice on control diet (Fig. 1). Food intake (measured in the
DNL study) was reduced on MCDD compared with both
control diet and CDD. However, mice were otherwise active
and healthy, displaying no external signs of distress.
Liver TG pool size was variable but similarly increased in
both CDD and MCDD mice compared with controls after 2 wk
of dietary intervention (Table 2).
Hepatic Inflammation
Steatohepatitis was confirmed in the MCDD mice, with
substantially increased plasma alanine aminotransferase (Table
2) and inflammatory infiltrate in the liver on immunohisto-
chemistry (Fig. 2). In contrast, there was no elevation in
plasma transaminases or liver inflammatory infiltrate in CDD
mice.
Fatty Acid Flux
Despite the loss of peripheral fat depots in the MCDD group,
the Ra of palmitate did not differ between the three groups
(Table 3). In keeping with this, fasting FFAs were not statis-
tically different: 670  62 vs. 602  91 vs. 887  220 mol/l
for CS, CDD, and MCDD, respectively.
The contribution of FFAs to TG pools was assessed in liver
and plasma. Despite marked differences in the fractional con-
tribution of plasma palmitate to liver TGs, there was no effect
of diet on the absolute contribution of plasma palmitate to the
liver triglyceride-derived palmitate pool. However, the contri-
bution of plasma palmitate to circulating TG palmitate was
reduced in MCDD mice.
DNL
MIDA of TG palmitate following ingestion of [13C2]acetate
is summarized in Table 4. There were no differences in
fractional synthesis rates, i.e., the percentage of newly synthe-
sized fatty acids contributing to the TG pool, between diets.
However, taking into account the differing hepatic TG pool
sizes, there was a marked increase in absolute rates of hepatic
DNL in MCDD mice, which was not detected in CDD mice.
To investigate the molecular basis for altered DNL, we under-
took real-time PCR analysis of mRNA levels in liver (Table 5).
However, mRNA levels for genes involved in DNL, acetyl-
CoA carboxylase-1 (ACC1), and fatty acid synthase (FAS)
were not altered in MCDD mice and were paradoxically
elevated in CDD mice. Moreover, mRNA levels for the
principal regulator of DNL, sterol regulatory element-bind-
ing protein-1c (SREBP-1c), were suppressed in MCDD
mice.
Despite increased hepatic DNL in MCDD mice, a smaller
amount of newly synthesized fatty acids appeared in the
plasma TG pool.
Table 3. Effect of choline  methionine deficiency on fatty acid flux measured by dilution of [13C4]palmitate tracer
CS CDD MCDD
Ra palmitate, mol  kg1  min1 27.16  3.46 26.25  2.27 28.34  3.46
Fractional contribution to liver TG pool, % 34.03  5.11 11.38  1.95*** 14.56  1.93***
Liver TG pool, mol/liver 23.98  3.69 51.27  6.15** 40.52  4.58*
Absolute contribution to liver TG pool, mol/liver 6.88  1.12 5.10  0.87 5.83  0.93
Fractional contribution to plasma TG pool, % 39.55  5.25 28.80  4.30 23.77  5.23
Plasma TG pool size, mol 0.67  0.05 0.67  0.06 0.46  0.3*/†
Absolute contribution to plasma TG pool, mol 0.26  0.04 0.19  0.04 0.11  0.03*
Data are means SE, analyzed by 1-way ANOVA with Tukey’s post hoc tests where appropriate. *P  0.05, **P  0.01, and ***P  0.001 vs. CS; †P  0.05
vs. CDD; n  12–15/group.
Table 4. Effect of choline  methionine deficiency on hepatic de novo lipogenesis and newly synthesized hepatic fatty
acid export
CS CDD MCDD
Liver
Acetyl CoA enrichment, % 7.6  0.6 8.9  0.5 7.2  0.3
Liver TG pool, mol/liver 25.0  2.3 38.2  4.0 48.5  5.0**
M  2 enrichment 0.104  0.009 0.121  0.008 0.132  0.007
M  4 enrichment 0.029  0.003 0.041  0.003* 0.036  0.003
Fractional synthesis rate, %/day 5.6  0.7 5.9  0.4 6.8  0.3
Absolute synthesis rate, mol/day 1.4  0.3 2.3  0.4 3.4  0.4**
Plasma TG
Acetyl-CoA enrichment, % 7.6  0.5 8.9  0.4 7.4  0.4
TG pool, mol 1.7  0.3 1.5  0.2 1.0  0.1*
Fractional synthesis rate, %/day 6.5  0.5 6.2  0.4 6.6  0.7
Absolute synthesis rate, mol/day 0.33  0.05 0.27  0.04 0.19  0.03*
Results are means  SE, analyzed by 1-way ANOVA with Tukey’s post hoc tests where appropriate. Absolute synthesis rates were calculated from mass
isotopomer distribution analysis of TG-derived palmitate following dietary [13C2]acetate labeling. The absolute synthesis rate of plasma TGs represents the
hepatic export of newly synthesized fatty acids. *P  0.05, **P  0.01 vs. CS; n  8/group, except for plasma TG data, where n  5–7/group.
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TG Export
Intravenous tyloxapol induced a linear increase in plasma
TG levels that was not altered in CDD mice but was markedly
reduced in MCDD mice (Fig. 3).
DISCUSSION
These data reveal marked differences in fatty acid metabo-
lism in mice fed MCDD vs. CDD, which may promote the
development of hepatocyte damage and steatohepatitis in the
MCDD but not CDD model at similar levels of total liver
triglyceride accumulation. Measurement of plasma triglycer-
ides after tyloxapol confirmed impaired hepatic triglyceride
export in the MCDD mice only, with palmitate and acetate
tracer administration demonstrating that export of both newly
synthesized and plasma-derived reesterified FFAs is impaired.
Reduced liver secretion of fatty acids (in VLDL), and hence,
supply to adipose tissue, rather than increased lipolysis and
adipose release of fatty acids, may therefore contribute to loss
of body fat in MCDD mice. In addition, hepatic DNL is
increased in MCDD mice, potentially exacerbating accumula-
tion of fatty acids as well as triglycerides in hepatocytes. In
contrast, in choline deficiency without methionine deficiency
(CDD) there were no significant changes in liver triglyceride
secretion, fatty acid turnover, or DNL. No increased fatty acid
esterification was measured in CDD mice by [13C4] dilution, as
hypothesized previously (36), although we cannot exclude that
a coexisting intrahepatic fatty acid pool that is not successfully
labeled exists in our tracer studies and contributes to triglyc-
eride accrual.
Both methionine and choline are key nutrients necessary for
the synthesis of phosphatidyl choline and export of VLDL
from the liver (27, 46). It has been widely assumed that hepatic
triglyceride accumulation in both CDD and MCDD is the result
of impaired VLDL export (reviewed in Ref. 22). Impaired
VLDL export has recently been confirmed using tyloxapol in
MCDD mice (37). However, in CDD mice this explanation is
based on an experiment that demonstrated reduced incorpora-
tion of radiolabeled palmitate tracer into plasma triglycerides
and retention of radioactivity in the liver in rats acutely (15 h)
after a CDD was introduced (29). These observations could be
explained by increased dilution of tracer in the expanded
triglyceride storage pool in liver from which VLDL is exported
or increased mitochondrial oxidation of palmitate and release
of radioactivity. Here, we show that CDD mice studied after 2
wk of dietary manipulation do not share an impairment of
hepatic VLDL export with MCDD mice. Not only was triglyc-
eride accumulation following tyloxapol normal in CDD mice,
but incorporation of palmitate tracer into plasma triglycerides
was intact following tracer palmitate or acetate administration.
This conclusion is supported by recent in vitro studies in mouse
liver cell lines (22).
The difference in VLDL export between CDD and MCDD
alone is unlikely to explain the contrasting risk of steatohepa-
titis. Both apolipoprotein B100 and the Mttp-encoded micro-
somal triglyceride transfer protein are essential for hepatic
triglyceride export, and deficiency of these proteins in both
mice and humans leads to hepatic steatosis (3, 26, 35, 41, 44)
but critically is not associated with the inflammation seen in the
MCDD model. However, impaired VLDL export may sensitize
Table 5. Effect of choline  methionine deficiency on mRNA levels in liver for genes involved in de novo lipogenesis
Gene Genbank Reference Sequence CS CDD MCDD
FAS NM_07988.3 5.98  2.47 30.64  8.46**††† 0.73  0.16
ACC1 NM_133360.2 7.72  1.10 2.14  0.63***†† 5.41  1.02
SREBP-1c NM_011480.1 9.02  2.22 5.21  1.46 3.18  0.88*
Data are expressed as means  SE and analyzed by 1-way ANOVA with Tukey’s post hoc comparison test where appropriate; n  5–8/group. Results are
expressed relative to internal control genes. FAS, fatty acid synthase; ACC1, acetyl-CoA carboxylase; SREBP-1c; sterol regulatory element-binding protein-1c.
*P  0.05, **P  0.01, and ***P  0.001 vs. CS; ††P  0.01 and †††P  0.01 vs. MCDD.
Fig. 3. Effect of methionine  choline deficiency
on plasma triglycerides following intravenous
tyloxapol. Hepatic triglyceride export was re-
duced in the MCDD group only. Data are ex-
pressed as means SE. Rate of triglyceride export
(142 21 vs. 122 15 vs. 80 7 mg·kg1·h1 for
CS, CDD, and MCDD, respectively) was calculated
from the linear portion of the graphs using Eq. 6 and
analyzed by 1-way ANOVA with Tukey’s post hoc
comparison test where appropriate; n 7–8/group.
*P  0.05 vs. CS.
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the liver to additional toxic insults, as evidenced by an increase
in lipopolysaccharide-induced inflammation in mice with re-
duced hepatic Mttp expression (5). Moreover, limited circum-
stantial evidence suggests that patients with steatohepatitis
have impaired apolipoprotein B-dependent triglyceride export
(43) and more frequent polymorphisms in the Mttp gene (42).
The impaired hepatic triglyceride export and steatosis found
in the apoB-38.9 mouse model of familial hypo-	-lipopro-
teinemia is associated with suppression of DNL, perhaps re-
flecting an adaptive mechanism (28). Using deuterium as a
tracer, DNL has previously been shown to be lower in C3H/
HeOuJ mice fed a high-sucrose lipogenic MCDD than in mice
fed a methionine/choline-supplemented lipogenic diet; how-
ever, in keeping with our findings, absolute DNL rates were
still markedly elevated on the lipogenic MCDD diet compared
with standard chow fed controls (39). DNL has not previously
been investigated in CDD mice using in vivo tracer techniques.
We found that DNL is markedly increased in MCDD mice but
not in CDD mice, although this result should be interpreted
with the caveat that the absolute synthesis rate calculation is
dependent on the hepatic triglyceride pool size, which surpris-
ingly was not significantly increased in the CDD group in the
DNL experiment (Table 4). The difference in DNL between
CDD and MCDD mice was also not statistically significant.
We opted to use a doubly labeled acetate tracer to improve
accuracy of GC-MS for MIDA, as suggested by Chinkes et al.
(7), although due to theoretical concerns over intrahepatic
acetyl-CoA gradients, the use of an acetate tracer may have
slightly underestimated DNL (2). Of note, we did not find that
in vivo changes in DNL were reflected in corresponding
changes in mRNA for ACC1 and FAS. This emphasizes the
importance of performing detailed in vivo metabolic studies; it
is well documented that the expression of single genes does not
necessarily translate to flux through complex metabolic path-
ways in vivo (16). The changes in mRNA levels may be
compensatory, e.g., if FAS is upregulated to compensate for
the downregulation of ACC1 in CDD mice and if the down-
regulation of SREBP-1c in MCDD mice, as documented pre-
viously (37), serves to “restrain” FAS and ACC1 expression in
the face of enhanced DNL.
It does not appear that alterations in fatty acid supply to the
liver from peripheral tissues is important in the MCDD or CDD
model. We studied mice after 2 wk of dietary manipulation
when the fatty liver phenotypes were established. Weight loss
in the MCDD mice was rapid initially and slowing by 2 wk
(Fig. 1). Therefore, it is possible that we have underestimated
any acute increase in peripheral fatty acid release. However,
increased peripheral fat turnover does not appear necessary to
maintain steatohepatitis. There is also debate as to whether the
Ra of palmitate should be expressed relative to fat mass,
fat-free mass, or total body weight (21). We expressed the Ra
of palmitate per unit of body mass to best represent the total
flux of fatty acids to the liver, although clearly the Ra of
palmitate would be higher in the MCDD group if expressed
relative to fat mass.
We have not made in vivo measurements of hepatic fatty
acid oxidation. These are difficult, particularly in mice. Even if
we had collected expired carbon dioxide or conducted indirect
calorimetry (1), this would not have been specific to hepatic
mitochondrial oxidation. Whole body 	-oxidation rates have
been shown to be elevated in MCDD mice, with an associated
increase in carnitine palmitoyltransferase IA activity and
palmitate oxidation measured ex vivo (39), although this was
not sufficient to increase plasma 	-hydroxybutyrate levels (37)
or compensate for the increased hepatic fatty acid load second-
ary to impaired VLDL export and increased DNL. There is
accruing evidence that fatty acid oxidation may be less efficient
in the MCDD model (40), leading to increased microsomal and
peroxisomal oxidation, generating reactive oxygen species and
lipid peroxides thought to be important in the pathogenesis of
inflammation and liver cell necrosis (23). Clearly, the impact in
the liver of increased FFA generation and impaired export, as
we have described here, would be exacerbated by any relative
failure of fatty acid oxidation (15). Another technical limitation
is that repeated sampling is not possible in mice to confirm that
steady state of tracer enrichments has been achieved. This may
be most relevant to the incorporation of labeled palmitate
within triglyceride pools, although even if steady state has not
been achieved, then the index we used in Eq. 2 is likely to
reliably reflect the rate of change. Finally, it would be ideal to
conduct pair-feeding experiments to match weight loss in CDD
and MCDD mice, although such is the severity of weight loss
in MCDD mice that this would be technically very challenging.
In summary, using a number of methodologies, including in
vivo tracer techniques, we have demonstrated important dif-
ferences in fatty acid metabolism that associate with contrast-
ing susceptibility to steatohepatitis in CDD and MCDD mice.
We speculate that the combination of abnormalities in fatty
acid metabolism in MCDD mice leads to accumulation of
FFAs within the liver that is disproportionate to the accumu-
lation of triglycerides and predisposes MCDD mice to com-
plications. It will be important to establish whether similar
changes in fatty acid metabolism are predictive of steatohepa-
titis and liver damage in other circumstances, including in
humans.
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